Biomarkers for detection of neonatal sepsis in biological fluid

A biological and neonatal technology, applied in the field of biomarkers, can solve the problems of increasing the risk of sepsis and increasing the cost of NICU care during hospitalization

Inactive Publication Date: 2012-01-25
霍洛吉克公司
View PDF12 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, prolonged hospital stays do not measurably increase the cost of NICU care and increase the risk of nosocomial sepsis from subsequent hospital-acquired microorganisms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for detection of neonatal sepsis in biological fluid
  • Biomarkers for detection of neonatal sepsis in biological fluid
  • Biomarkers for detection of neonatal sepsis in biological fluid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Example 1: Using a global proteomic approach to identify cord blood biomarkers for neonatal sepsis

[0088] experimental method

[0089] Sample Collection: Cord blood samples from a prospective observational cohort of 82 women in spontaneous preterm labor at 20-34 weeks' gestation were analyzed. Early-onset neonatal sepsis was defined as positive neonatal blood cultures within 72 hours of delivery. Of the 82 subjects, 71 delivered at less than 34 weeks, and 5 neonates had confirmed neonatal sepsis (positive blood cultures in newborns), while 8 neonates had suspected sepsis (positive blood cultures Negative, suggesting clinical symptoms of infection) diagnosis.

[0090] Immunodepletion of umbilical cord serum: Serum samples for 2-DLC experiments were depleted of the 12 most abundant proteins (albumin, IgG, IgA, IgM, α -1 antitrypsin, transferrin, haptoglobin, alpha-1 acid glycoprotein, alpha-2 macroglobulin, fibrinogen, apolipoproteins A-I and A-II). Appropriate fr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention concerns the identification and detection of biological fluid biomarkers of neonatal sepsis using global proteomic approaches.

Description

field of invention [0001] The present invention concerns the use of a global proteomic approach to identify and detect biomarkers of neonatal sepsis and neonatal sepsis-related complications in biological fluids. Background of the invention [0002] Sepsis is a serious problem in neonates admitted to neonatal intensive care. It is associated with increased mortality, morbidity, and length of hospital stay. As such, the human and financial costs of these infections are both high. Possible ("excluded" or "suspected") early-onset sepsis remains the most common admission diagnosis to the neonatal intensive care unit (NICU). Although the rate of early-onset sepsis increases with the degree of both prematurity and low birth weight, specific laboratory tests have not been shown to be accurate enough to allow identification of a "true" bloodstream infection and thus need for a course of antibiotics treated patients. Thus, antibiotic use is many times the rate of "proven" sepsis,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N2800/26G01N33/6893G01N2800/60G01N2550/00
Inventor S.纳加拉M.格拉维特
Owner 霍洛吉克公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap